Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study
The recommended phase II dose is ribociclib 400 mg followed by doxorubicin 60 mg/m2, which demonstrated an acceptable toxicity profile.
Authors
- Gordon Brent Mills (ORCID: https://orcid.org/0000-0002-0144-9614)
- Janét Pittsenbarger
- Jessica L. Davis (ORCID: https://orcid.org/0000-0002-2725-1518)
- Emile Latour (ORCID: https://orcid.org/0000-0002-7749-7217)
- Nathan McMahon
- Christopher W. Ryan (ORCID: https://orcid.org/0000-0002-4259-1123)
- Monika A. Davare (ORCID: https://orcid.org/0000-0003-1802-7597)
- Florence Choo (ORCID: https://orcid.org/0000-0002-7904-8271)
- Go Nishikawa (ORCID: https://orcid.org/0000-0003-2253-7274)
- Byung Park
- Reid Burch
- Limin Zhu (ORCID: https://orcid.org/0000-0002-8723-7427)
- Lara Emily Davis (ORCID: https://orcid.org/0000-0002-6480-1611)
- Kevin D. Nusser
Institutions
- Indiana University Health (US)
- Oregon Health & Science University (US)
- Rocky Mountain Hospital for Children (US)
- OHSU Knight Cancer Institute
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4001
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Cancer Institute